Mill Creek, WA, United States of America

Evgeniy S Belousov

This inventor holds 6 USPTO granted patents, plus 1 CIPO patent. Top assignees: Elitech Holding B.v., Epoch Biosciences, Inc., Epoch Pharmaceuticals, Inc.. Active years: 2001-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Evgeniy S Belousov. Retrieved from https://idiyas.com/inventor/evgeniy-s-belousov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 33.3


Average Co-Inventor Count = 6.0

ph-index = 5

Forward Citations = 268(Granted Patents)


Company Filing History:


Years Active: 2001-2013

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Evgeniy S Belousov: Innovator in Oligonucleotide Technology

Introduction

Evgeniy S Belousov is a prominent inventor based in Mill Creek, WA (US). He has made significant contributions to the field of oligonucleotide technology, holding a total of six patents. His work focuses on enhancing the specificity and efficiency of hybridization and mismatch discrimination in genetic analysis.

Latest Patents

One of his latest patents involves hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders. This innovation utilizes conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI), and oligonucleotides. These conjugates form unusually stable hybrids with complementary target sequences, where the tethered CDPI group resides in the minor groove of the duplex. Due to their high binding affinity, conjugates as short as 8-mers can be employed as amplification primers with remarkable specificity and efficiency. The MGB conjugation enhances the discriminatory power of short oligonucleotides, allowing for improved detection of nucleotide sequence mismatches. The MGB-conjugated probes and primers facilitate various analytic and diagnostic procedures, including amplification reactions, PCR, detection of single-nucleotide polymorphisms, gene hunting, differential display, and hydrolyzable probe assays. This advancement allows for the use of shorter oligonucleotides, which exhibit higher specificity and better discriminatory power.

Career Highlights

Throughout his career, Evgeniy has worked with notable companies such as Epoch Pharmaceuticals, Inc. and Elitech Holding B.V. His expertise in oligonucleotide technology has positioned him as a key figure in the field, contributing to advancements that have significant implications for genetic research and diagnostics.

Collaborations

Evgeniy has collaborated with esteemed colleagues, including Joel Hedgpeth and Irina Aleksandrovna Afonina. These partnerships have further enriched his work and expanded the impact of his innovations in the scientific community.

Conclusion

Evgeniy S Belousov's contributions to oligonucleotide technology exemplify the importance of innovation in genetic research. His patents and collaborations highlight his commitment to advancing the field and improving diagnostic procedures.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…